Showing 1471-1480 of 6808 results for "".
DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.Humira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaExpanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.What Should Dermatology PAs Know About Training and Onboarding
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-know-about-training-and-onboarding/24395/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses what realistic expectations PAs should have while training and onboarding in a new practice. Topics include what new PAs should expect at 30, 60, and 90 daysDermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinInsights on Care for Skin of Color, Part 2
https://practicaldermatology.com/topics/skin-of-color/insights-on-care-for-skin-of-color-part-2/18185/Hilary Baldwin, MD and James Q. Del Rosso, DO continue their discussion with host Neal Bhatia, MD about managing skin of color. They address long-term management strategies and the need for cultural awareness.Advances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futUpdates in Pediatric Dermatology
https://practicaldermatology.com/topics/psoriasis/updates-in-pediatric-dermatology/19733/2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A four